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Abstract
Patients affected by chronic inflammatory disorders display high amounts of soluble CD95L. This homotrimeric ligand arises
from the cleavage by metalloproteases of its membrane-bound counterpart, a strong apoptotic inducer. In contrast, the
naturally processed CD95L is viewed as an apoptotic antagonist competing with its membrane counterpart for binding to
CD95. Recent reports pinpointed that activation of CD95 may attract myeloid and tumoral cells, which display resistance to
the CD95-mediated apoptotic signal. However, all these studies were performed using chimeric CD95Ls (oligomerized
forms), which behave as the membrane-bound ligand and not as the naturally processed CD95L. Herein, we examine the
biological effects of the metalloprotease-cleaved CD95L on CD95-sensitive activated T-lymphocytes. We demonstrate that
cleaved CD95L (cl-CD95L), found increased in sera of systemic lupus erythematosus (SLE) patients as compared to that of
healthy individuals, promotes the formation of migrating pseudopods at the leading edge of which the death receptor
CD95 is capped (confocal microscopy). Using different migration assays (wound healing/Boyden Chamber/endothelial
transmigration), we uncover that cl-CD95L promotes cell migration through a c-yes/Ca
2+/PI3K-driven signaling pathway,
which relies on the formation of a CD95-containing complex designated the MISC for Motility-Inducing Signaling Complex.
These findings revisit the role of the metalloprotease-cleaved CD95L and emphasize that the increase in cl-CD95L observed
in patients affected by chronic inflammatory disorders may fuel the local or systemic tissue damage by promoting tissue-
filtration of immune cells.
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Introduction
Screening for death inducers led to the discovery of the receptor
CD95, which was initially cloned and described as a death
receptor belonging to the TNF-R family [1,2]. Since CD95 is
devoid of enzymatic activity, both aggregation [3] and conforma-
tional modification [4] of the receptor are crucial to recruit the
adaptor protein FADD, which in turn aggregates initiator
caspases-8 and -10. On binding of CD95L to CD95, the death
receptor clusterized and polarized in a structure designated the
CD95-CAP [5,6]. The local concentration of caspases is followed
by their cleavage and the release in the cytoplasm of active
caspases culminating in the induction of an apoptotic signal [7].
We and others showed that depending on the extent of CD95
mobilization, it is possible to convert CD95 into a non-apoptotic
signaling receptor [8–10].
Expression of the CD95 ligand, CD95L, is tightly controlled
and is found at the plasma membrane of activated T-lymphocytes
and NK cells where it participates in immune surveillance and in
peripheral tolerance [11]. As a consequence, failure of the CD95/
CD95L signalling leads to auto-immunity [12] and increased risk
of cancer [13,14].
Recent evidence pinpointed that CD95L behaves as a chemo-
attractant molecule for neutrophils and macrophages [15–17] and
for malignant cells in which the CD95-mediated apoptotic signal is
non-productive [18,19]. Nonetheless, the biological role of CD95L
has to be clarified due to the fact that physiologically, the ligand is
present under two main forms with different stoichiometries.
Whereas the membrane-bound CD95L induces a potent apoptotic
signal, the physiological and pathological role of the metallopro-
tease-cleaved CD95L remains poorly defined. Indeed, most studies
on CD95L are focused on membrane-bound or engineered
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death. Initial studies focusing on the apoptotic signal induced by
CD95 showed that the homotrimeric CD95L behaves as a
competitive inhibitor of its membrane-bound counterpart [20,21].
More recently, the antagonist role of cleaved CD95L (cl-CD95L)
has been challenged by Strasser’s group [22]. Indeed, they found
that ectopic expression of the soluble CD95L in a CD95L-
deficient mouse strain dramatically aggravated the lupus-like
disease and the occurrence of histiocytic sarcoma compared to
mice
gld/gld expressing a mutated CD95L incapable of CD95
binding. As a consequence, we may envision that soluble CD95L
promotes autoimmunity and tumorigenesis through unknown
non-apoptotic activities [22].
Cell migration is a multifactorial and multi-step process
involving the formation of lamellipodia/pseudopodia, cell body
contraction, and tail retraction [23]. For instance, production of
phosphatidylinositol-(3,4,5)-trisphosphate (PIP3), formation of
actin mesh, and localized Ca
2+ rise are common features of
migrating cells [23,24]. Class I PI3K phosphorylates plasma
membrane phospholipids and generates the second messenger
PIP3, which serves as docking sites for various signaling factors.
The cytosolic serine-threonine kinase Akt binds PIP3 via its
pleckstrin homology domain (PH domain) and thus redistributes to
the plasma membrane. Once at the membrane, Akt is activated
through phosphorylation on two sites by the PI3K-dependent
kinase-1 (PDK1) on Thr
308 and by mTOR (mammalian target of
rapamycin) complex-2 on Ser
473.
Chronic inflammatory disorders such as systemic lupus
erythematosus (SLE) achieve massive infiltration of organs
with cells from innate (neutrophils/macrophages) and adaptive
(activated T-lymphocytes) immune systems [25]. The initial
steps involved in the attraction of these cells remains to be
deciphered. Herein, we ascertain that the naturally processed
CD95L is increased in SLE patients and this cytokine does not
induce the ‘‘orthodox’’ apoptotic signal but rather ignites a
c-yes/Ca
2+/PI3K signaling pathway, which promotes cell
migration.
Results
The Metalloprotease-Cleaved CD95L Does Not Induce
Caspase-8 Activation and Cell Death
Physiologically, the plasma membrane homotrimeric ligand is
released after cleavage of its ectodomain by metalloproteases
between either serine 126 and leucine 127 [20] or lysine 129 and
glutamine 130 [26]. Since a recent study described that the soluble
form may contribute to the aggravation of a lupus-like disease in
mice [22], we explored the effect of cl-CD95L on activated
lymphocytes. To produce cleaved CD95L (cl-CD95L), we trans-
fected the epithelial kidney cells 293 with wild type CD95L-
encoding cDNA. These cells secrete exosomes, which contain full-
length CD95L, and thus contaminate supernatants. Therefore, to
eliminate this potential contaminant, supernatants from wild type
CD95L-transfected 293 cells underwent an ultracentrifugation step
to pellet the secreted vesicles [20]. As expected, CD95L-transfected
human epithelial kidney 293 cell line produced full-length plasma
membrane-bound CD95L (<40 kDa) (Figure S1A) and pelleted
exosomes also contained full-length CD95L (Figure S1A). Cleaved-
CD95L was found in exosome-free supernatant at a lower
molecular weight (<30 kDa) than the full-length ligand (Figure
S1A). In contrast, supernatants harvested from 293 cells expressing
a CD95L in which serine 126 and leucine 127 were replaced by
glutamic acid (CD95L
S126E/L127E) [20], the putative cleavage site of
metalloprotease, exhibited a dramatic decrease in their amounts of
soluble CD95L, confirming that CD95L was cleaved between these
amino acids (Figure S1A). The faint amount of soluble CD95L
found in CD95L
S126E/L127E-transfected 293 cells may be due to the
presence of another cleavage site (i.e., Lys129/Gln130) since a shift
of this cleavage site has also been described [26].
Next, we confirmed the homotrimeric stoichiometry of the
cleaved CD95L using gel filtration (Figure S1B). In the purpose of
generating a multi-aggregated and highly cytotoxic ligand, several
CD95L-containing constructs have been engineered. As already
reported, we have generated a dodecameric CD95L (gel filtration
analysis, unpublished data) through the fusion of the extracellular
region (a.a. 105 to 281) of CD95L with a dimerization domain (Ig)
derived from the LIF receptor gp190 [27]. Although the Ig-
CD95L triggered induction of the initiator caspase-8 and cell
death (Figure S1C and S1D), cl-CD95L failed to initiate either
cleavage of caspase-8 (Figure S1C) or apoptosis (Figure S1D).
Overall, these findings support the conclusion that in contrast
to the multi-aggregated forms of CD95L, which mimic the
membrane-bound ligand, homotrimeric cl-CD95L does not
achieve induction of the ‘‘orthodox’’ CD95-mediated apoptotic
signal.
Cleaved-CD95L Induces the Formation of CD95-CAP
It has been described that soluble CD95L acts as an inert ligand,
which once bound to CD95 competes with the membrane-bound
CD95L and prevents the transmission of the apoptotic signal
[20,21]. Consistent with this statement, cells incubated with cl-
CD95L did not undergo caspase-8 activation or cell death (Figure
S1C and S1D). Nevertheless, cl-CD95L was able to induce
proximal events of the CD95 signal up to the formation of CD95-
CAP (Figure 1A). Strikingly, once incubated with 100 ng/ml
(3.3 nM) of cl-CD95L, classical round-shaped activated T-
lymphocytes underwent a dramatic alteration of their morphology
and emitted pseudopods (red arrows, Figure 1A). Formation of
CD95-CAP and pseudopods in the presence of cl-CD95L was also
observed with the leukemic T-cell lines H9 and Jurkat (Figure
S2A–C). In contrast, incubation of activated lymphocytes with the
dodecameric Ig-CD95L triggered cell blebbing and shrinkage,
Author Summary
The ‘‘death receptor’’ CD95 (also known as Fas) plays an
essential role in ensuring immune tolerance of self
antigens as well as in the elimination of the body’s cells
that have been infected or transformed. This receptor is
engaged by the membrane-bound ligand CD95L, which
can be released into blood circulation after cleavage by
metalloproteases. Hitherto, most of the studies on the
CD95 signal have been performed with chimeric CD95Ls
that mimic the membrane-bound ligand and exhibit a
level of aggregation beyond that described for the
metalloprotease-cleaved ligand. Multi-aggregated CD95L
elicits a caspase-driven apoptotic signal. In this study, we
observe that levels of soluble and naturally processed
CD95L in sera of patients suffering from lupus correlate
with disease severity. Strikingly, although this soluble
CD95L fails to trigger cell death unlike its chimeric version,
it induces a ‘‘non-canonical’’ Ca
2+/c-yes/PI3K-dependent
signaling pathway that promotes the transmigration of T-
lymphocytes across the endothelial barrier. These findings
shed light on an entirely new role for the soluble CD95L
that may contribute to local or systemic tissue damage by
enhancing the infiltration of activated T-lymphocytes.
Overall, these findings underline the importance of
revisiting the role of this ‘‘apoptotic cytokine’’ in the
context of chronic inflammatory disorders.
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Alteration of cell morphology and formation of CD95-CAP
was not restricted to hematological cells since the fibroblastic
PS120
CD95 cell line, derived from PS120, a CD95-deficient cell
that has been reconstituted with wild type human CD95 (Figure
S3A), also underwent alterations of its morphology in the presence
of cl-CD95L (Figure 1C). Indeed flat, cubical epithelial shape was
converted to bipolar, well-oriented, slanted, fibroblastic appear-
ance following incubation with 100 ng/ml of cl-CD95L
(Figure 1C). Similarly to lymphocytes, clustering of CD95 was
observed at the extremity of the emitted pseudopods in the
fibroblastic cell line (Figure 1C).
Cleaved-CD95L Induces the Emission of PIP3/Ca
2+/F-
Actin-Containing Pseudopods
The initial response of a cell to a migration-promoting agent is
to emit protrusions in the direction of migration. These
protrusions can be large, broad lamellipodia or more slender
and filiform structures such as pseudopods and are usually driven
by actin polymerization [23]. Several studies established that an
intracellular calcium rise and an activation of PI3K play a
crucial role to achieve cell motility [28–31]. These signals
contribute to the remodeling of actin cytoskeleton, which in
association with myosin motors elicits the mechanical process of
cell movement. We then investigated whether although unable to
trigger caspase activation, cl-CD95L induced remodeling of
actin, Ca
2+ response, and activation of the PI3K signaling
pathway.
Using the non-competing molecule Lifeact, a small peptide,
which has recently been described to bind polymerized actin and
to not interfere with actin dynamics [32], we clearly observed that
the pseudopods emitted by leukemic T-cells concentrated a dense
meshwork of polymerized actin (Figure 2A). The serine-threonine
kinase Akt is a downstream effector of the PI3K signal and its
phosphorylation on its serine
473 is a key feature of its activation. As
shown in Figure 2B, T-cell lines incubated with cl-CD95L
underwent a potent Akt phosphorylation. To confirm that
cl-CD95L behaved as an inducer of the PI3K/Akt signal, we
analyzed the impact of the naturally processed ligand on the
production of the plasma membrane PIP3. For this purpose, we
expressed in T-cells a chimeric protein encompassing GFP fused to
the pleckstrin homology domain of Akt (PHAkt-GFP), which
possesses a strong affinity to the negatively charged lipid. Addition
Figure 1. Cl-CD95L elicits CD95-CAP formation. (A) Activated (PHA/IL2)-peripheral blood T-lymphocytes (PBLs) from healthy individuals were
incubated with or without 100 ng/ml of cl-CD95L for 30 min. Cell morphology was followed using phase contrast microscopy and CD95 was stained
using a mouse anti-CD95 mAb (APO1-3) followed by a goat Alexa488-coupled anti-mouse IgG mAb. Red arrows depict emitted pseudopods
(Bars=5 mm). (B) PHA/IL2-activated PBLs were incubated with the cytotoxic Ig-CD95L for indicated times, and cells were analyzed as described in (A).
White arrows depict blebs emitted by apoptotic cells (bars=5 mm). (C) The fibroblastic cell line PS120 devoid of endogenous CD95 (PS120
control)o r
reconstituted with human wild type CD95 (PS120
CD95) were untreated or treated with 100 ng/ml of cleaved CD95L for indicated times, and cell shape
and CD95 distribution were analyzed.
doi:10.1371/journal.pbio.1001090.g001
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cytoplasmic localization of PHAkt-GFP in resting cells changed for
a plasma membrane reorganization (Figure 2C). Overall these
findings highlighted that the naturally processed CD95L activates
the PI3K/Akt signaling pathway.
On the grounds that spatiotemporal distribution of ‘‘calcium
microdomains’’ orchestrates directional movement during cell
migration [33], we further investigated the effects of cl-CD95L on
the intracellular distribution of Ca
2+ using video-microscopy and
we established that T-lymphocytes incubated with cl-CD95L
Figure 2. Cleaved CD95L triggers a pseudopod-localized actin/PI3K/Akt signal and a Ca
2+ entry through activation of the CRAC
channel Orai1. (A) H9 T-cells were transiently transfected with the actin marker Lifeact-GFP. Living cells were harvested (Ficoll) and treated or
untreated for 30 min with 100 ng/ml of cleaved CD95L. Cells were fixed, and CD95 was stained using anti-CD95 mAb (APO1-3) and revealed with the
secondary Alexa555-coupled Goat anti-mouse antibody (red). Nuclei were stained using DAPI (blue). Bars=5 mm. Images were acquired with an
ApoPLAN 636objective. (B) The leukemic T-cell line H9 was incubated with 100 ng/ml of the naturally processed CD95L for indicated times. Cells
were lysed, and for each lane, 100 mg of protein were loaded. Proteins were resolved by SDS-PAGE and anti-whole Akt and anti-Akt phosphorylation
(serine
473) immunoblots were performed. Akt phosphorylation stands for its activation. (C) The pleckstrin homology (PH) domain of Akt binds PIP3
produced by PI3K activation. As a consequence, the probe PHAkt-GFP stains PIP3. H9 T-cells were transiently transfected with the PHAkt-GFP construct
(green). Living cells were isolated (Ficoll) and incubated with 100 ng/ml of the naturally processed CD95L (cl-CD95L) for 30 min. Cells were fixed, and
CD95 was stained as previously mentioned (red). Pictures were taken by confocal microscopy. Cell morphology was followed using differential
interference contrast microscopy. Nuclei were stained with DAPI (blue). Bars=5 mm. (D) Calcium measurement in single cell. Jurkat T-cells were loaded
with the permeant calcium probe Fura-2AM, and in parallel, CD95 was followed using an anti-CD95 mAb and an Alexa555-coupled goat anti-mouse
mAb as described in Materials and Methods. Cells were bathed in a Ca
2+-free medium and pre-incubated (lower panel; cl-CD95L) or not (upper panel;
unstimulated) with cl-CD95L (100 ng/ml). 2 mM Ca
2+ was added when indicated by the black-filled rectangle. Ratio images (F340 nm/F380 nm) were
taken every 5 s, and the images shown correspond to the indicated period of time. Grey level intensities were translated to false colors according to
the colors scale shown at the right, and [Ca
2+]i was estimated from the ratio values and calibration experiments as described in Materials and
Methods. Red arrows indicate the CD95-CAP. (E) Jurkat T-cells were treated or untreated with 100 ng/ml of cl-CD95L for 60 min. Cells were fixed and
Orai1 and CD95 were stained as described in Materials and Methods. Cell morphology was analyzed using phase contrast microscopy. (F) Left panels:
GFP-, GFP-Orai1, or GFP-Orai1E106A-expressing Jurkat T-cells were loaded with 1 mM of the calcium probe Fura-2AM for 30 min at RT. Cells were
bathed at 37uC in a medium containing 2 mM [Ca
2+]e and then treated with 100 ng/ml of cl-CD95L (black arrow). GFP#84 corresponded to control
cells expressing GFP. GFP-Orai1E106A#155 and #169 corresponded to two independently isolated clones expressing the non-functional CRAC
channel. GFP-Orai1#142 corresponded to Jurkat cells overexpressing human Orai1. Values were recorded every 10 s. Right panel: For each
experiment, the area under the curve (AUC) was measured for 1,000 s, and the statistical analyses of the AUC values were performed for indicated
cells using non-parametric two-tailed Mann-Whitney tests. ** and *** indicate p values#0.01 and 0.001, respectively.
doi:10.1371/journal.pbio.1001090.g002
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2+ concentration at the leading
edge of the pseudopod (Figure S4), beneath the CD95-CAP
(Figure 2D).
Activation of a wide variety of plasma membrane receptors
elicits a rapid biphasic Ca
2+ response through the induction of
phospholipase C (PLC) that generates inositol 1,4,5-trisphosphate
(IP3), which in turn activates the IP3-receptors present in the
membrane of the endoplasmic reticulum (ER). IP3-R activation
drives the release of the ER-stored Ca
2+ [34]. The second phase of
the Ca
2+ signal is mainly achieved by activation of the store-
operated Ca
2+ (SOC) channels in the plasma membrane that
induce a Ca
2+ influx [35]. In order to address the cl-CD95L-
mediated molecular mechanism evoking the Ca
2+ response, we
first investigated whether PLCc1 participated in this signal.
Phosphorylation of PLCc1 on its tyrosine 783 indicated that the
lipase was activated in the presence of cl-CD95L (Figure S5A). To
prove that PLCc1 participated in the cl-CD95L-mediated Ca
2+
rise, we analyzed the cl-CD95L-mediated Ca
2+ signal in PLCc1-
deficient T-cells (Figure S5B). The Ca
2+ signal was abrogated in
the PLCc1-deficient T-cells, while it was restored in the PLCc1-
reconstituted counterpart (Figure S5B). Second, T-cells pre-
incubated with the IP3-R inhibitors, 2-APB (Figure S5C and
S5D) and xestospongin C (unpublished data), failed to mobilize
Ca
2+ in the presence of cl-CD95L, indicating that the homo-
trimeric ligand elicited the Ca
2+ signal through activation of
PLCc1 and the subsequent induction of the IP3-receptors.
In nonexcitable cells, SOC influx is the major Ca
2+ entry
mechanism [35,36]. Recently it has been ascertained that two
genes, STIM1 (stromal interaction molecule 1) and Orai1,
participate in the SOC entry [37–41]. While STIM1 behaves as
an ER-localized Ca
2+ sensor, Orai1 is a pore-forming component
of the SOC channel [42,43]. To finely identify the molecular
mechanism that drives the Ca
2+ rise observed in the presence of cl-
CD95L, we first explored whether the extracellular Ca
2+
contributed to the cl-CD95L-mediated Ca
2+ signal. In T-cell lines
bathed in a Ca
2+-free medium, the cl-CD95L-mediated Ca
2+
signal was significantly reduced as compared to regular medium
(Figure S6A and S6B). These findings suggested that Ca
2+ influx
participated in the cl-CD95L-induced Ca
2+ response. To inves-
tigate the role played by the SOC channels on the cl-CD95L-
mediated Ca
2+ response, we analyzed the effect of the pharma-
cological inhibitor of SOC channels termed BTP2 [44] on this
Ca
2+ signal. Pre-incubation of peripheral blood lymphocytes
(PBLs) with BTP2 reduced the magnitude of the Ca
2+ peak and
abrogated the Ca
2+ plateau observed in the presence of the
metalloprotease-processed cl-CD95L (Figure S6C), suggesting that
the SOC channels contributed to Ca
2+ entry upon the addition of
cl-CD95L. Next, the role of Orai1 in the cl-CD95L-driven Ca
2+
entry was studied. Confocal microscopy revealed that addition of
cl-CD95L led to the compartmentalization of Orai1 into the
CD95-CAP (Figure 2E). Substitution of the conserved glutamate
in position 106 to an alanine (Orai1E106A) results in a non-
conducting Orai1 channel acting as a dominant negative construct
that abrogates the native SOC current [40,42,43]. Consequently,
we generated leukemic T-cell clones stably expressing the Orai1
mutant or over-expressing the wild type Orai1 and we assessed the
Ca
2+ response induced by cl-CD95L. Compared to GFP-
expressing control cells, the ectopic expression of Orai1E106A
dramatically reduced the amplitude and the duration of the Ca
2+
response (Figure 2F). On the other hand, over-expression of Orai1
resulted in a significant increase in the intensity and the duration
of the CD95-mediated Ca
2+ response (Figure 2F). Overall, these
findings established that in the presence of cl-CD95L, T-cells elicit
aC a
2+ response through a PLCc1/IP3R/Orai1 signaling pathway
at the leading edge of the emitted pseudopod in a structure that
may contribute to cell migration.
cl-CD95L Promotes Cell Migration through a Death-
Domain Dependent Signal
Next, we addressed the impact of the metalloprotease-processed
CD95L on cell migration by using Boyden chamber and wound
healing assays. For this purpose, we reconstituted the CD95-
deficient PS120 cell line with either wild type CD95 (PS120
CD95)
or death-domain truncated counterpart (PS120
CD95(D1-210)) (Figure
S3A). In contrast to the parental PS120 or PS120
CD95(D1-210),
PS120
CD95 exhibited a sensitivity towards the multimeric
Ig-CD95L (Figure S3B), which indicated that the intracellular
CD95 machinery remained functional in these cells. As expected,
cl-CD95L did not trigger cell death in the different PS120 cell lines
(Figure S3B). Strikingly, we found that in contrast to PS120 and
PS120
CD95(D1-210) cells, migration of PS120
CD95 cells was stimu-
lated in the presence of cl-CD95L (Figure 3A and 3B), indicating
that a functional death domain was required to mediate the cl-
CD95L effects on motility. To confirm the role of cl-CD95L on
cell motility, wound-healing assays were carried out. Fibroblasts
were grown to confluency, and a ‘‘wound’’ was realized in the cell
monolayer. While in the presence of cl-CD95L cells devoid of
CD95 or expressing a DD-deficient CD95 failed to fill the gap
after 24 h, the CD95-reconstituted PS120 completely healed the
‘‘wound’’ (Figure 3C). In addition, incubation with cl-CD95L did
not modify the cell proliferation rate (unpublished data). Overall,
these findings led to the conclusion that cl-CD95L induces a DD-
dependent signal, which promotes migration of the CD95-
expressing cells.
Cl-CD95L Causes an Orai1- and PI3K-Dependent Program
of Cell Migration
As the death domain of CD95 was crucial to mediate the motile
signal, we next analyzed whether this intracellular region was also
mandatory to induce Akt phosphorylation upon addition of
cl-CD95L. We did not observe any Akt phosphorylation in
PS120
control and PS120
CD95(D1-210) cells (Figure 4A). Conversely,
expression of wild type CD95 restored the transmission of the
PI3K/Akt signal upon cl-CD95L addition (Figure 4A). Since
interconnections have been reported between Ca
2+ and PI3K/Akt
signaling pathways, we next investigated whether the cl-CD95L-
mediated Ca
2+ response contributed to the magnitude of the Akt
activation level. To prevent the cl-CD95L-mediated calcium
response, cells were pre-treated with the calcium chelator BAPTA-
AM and 2-APB, an inhibitor of inositol 1,4,5-trisphosphate
receptor (IP3R) and store-operated calcium (SOC) channels.
Inhibition of the cl-CD95L-induced Ca
2+ response using
BAPTA-AM or 2-APB decreased by 60% and 70% the amount
of Akt phosphorylation (Figure 4B), respectively, indicating that
the Ca
2+ rise observed upon addition of cl-CD95L enhanced the
activation level of Akt.
Next, the role played by Ca
2+/PI3K signals in the CD95L-
mediated cell motility was investigated. Non-cytotoxic and non-
cytostatic amounts of the PI3K inhibitors LY294002, a quercetin
analogue [45], or Wortmannin, a fungal metabolite, dramatically
reduced the cl-CD95-mediated cell motility (Figure 4C and 4D).
Likewise, BAPTA-AM and 2-APB, which both prevented the
cl-CD95L-mediated Ca
2+ response (Figure S5C and S5D, S7A
and S7B), significantly impeded cell migration (Figure 4C and
4D). Indeed, we found that inhibition of PI3K activity by
LY294002 and Wortmannin reduced cell motility by 75% and
83%, respectively. On the other hand, down-modulation of the
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2+ response by either BAPTA-AM or 2-APB
achieved 47% and 71% of cell migration blockade, respectively.
We next examined the effects of small-molecule inhibitors of class I
PI3Ks to explore the contribution of the different isoforms in the
cl-CD95L-mediated cell migration. While the catalytic subunits
p110a and p110b are ubiquitously expressed, p110d and p110c
are found predominately in hematological cells [46]. By screening
for p110 isoform-selective PI3K inhibitors (Figure S8A) that could
prevent the cl-CD95L-mediated cell migration, we observed that
whereas p110-c was instrumental in both the Akt activation and
the transmigration of H9 T-cells across a barrier of endothelial
cells (Figure S8B and S8D), the a and b isoforms orchestrated the
motility process in the non-hematological cell line PS120
CD95
(Figure S8C and S8E). These findings definitively proved that the
cl-CD95L-mediated motility signal occurred through the class I
PI3K activation and that the implicated isoform varied between
hematological and non-hematological cells. Finally, we wondered
whether Orai1 contributed to the cl-CD95L-mediated cell
migration. To address this question, HEK cells were transiently
transfected with either scrambled or Orai1-targeting shRNA
(Figure 4E). Orai1 knock-down in HEK cells reduced the SOC
current by 85% [47]. Strikingly, the silencing of Orai1 abrogated
the cl-CD95L-mediated cell migration (Figure 4F), strongly
supporting the conclusion that the Orai1-driven Ca
2+ entry
contributed to the motility signal induced in the presence of cl-
CD95L. Altogether, these findings underlined that the metallo-
protease-cleaved CD95L does not behave as an inert ligand but
rather stimulates cell migration through an Orai1/Ca
2+/PI3K-
dependent mechanism.
Cleaved CD95L Activates the PI3K/Akt Signal Through
the src Kinase c-Yes
Induction of the CD95-mediated PI3K/Akt response remains
poorly defined. However, it is established that activation of PI3K
can be reached through activation of src kinases [48], which are
found enriched into sub-domains of the plasma membrane
designated lipid rafts [49]. In this regard, src kinases are anchored
Figure 3. Cleaved CD95L promotes cell migration through a DD-dependent signal. (A) The CD95-deficient PS120 and its counterparts
expressing human wild type CD95 or DD-truncated CD95 were seeded in a Boyden chamber in the presence or absence of cl-CD95L (100 ng/ml) and
incubated for 24 h. The filter was removed, the upper side containing the non-migrating cells was wiped out with cotton-tipped swabs, and
migrating cells in the opposite side of the filter were fixed with methanol and stained (Giemsa). For each experiment, five pictures of random fields
were taken and a representative picture was depicted (Bars=70 mm). (B) Cells were treated as described in (A). To quantify cell motility, Giemsa-
stained migrating cells from the lower side of the membrane were lyzed and absorbance was measured at 560 nm. (C) Wound healing assay, a
confluent monolayer of the indicated cells was ‘‘wounded’’ with a tip and then cells were incubated for 24 h in the presence or absence of 100 ng/ml
of cl-CD95L and pictures were acquired (Bars=50 mm). Pictures are representative of 5 independently performed experiments.
doi:10.1371/journal.pbio.1001090.g003
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myristoylation) of their amino-terminal sequence [50]. Lipid rafts
were tagged using the amino-terminal domain of the src kinase
Lck fused to the fluorescent protein GFP [51], and we examined
whether cl-CD95L enabled the compartmentalization of CD95
into lipid rafts, meaning in close vicinity of the src kinases. While
T-cells displayed a homogeneous distribution of the Lck-GFP
probe at the plasma membrane, addition of cl-CD95L partitioned
CD95 into lipid rafts at the leading edge of the pseudopod
(Figure 5A). To follow lipid rafts in activated PBLs, we incubated
cells with a fluorescent-conjugated cholera toxin B sub-unit that
exhibits strong affinity for the monosialoganglioside GM1, a lipid
enriched into lipid rafts [52]. We confirmed that cl-CD95L
achieved the partition of CD95 into lipid rafts at the leading edge
Figure 4. cl-CD95L promotes a cell migration through a Ca
2+/PI3K/Akt signal. (A) The CD95-deficient fibroblastic cell line PS120 transfected
with empty vector (PS120
control) or reconstituted with either human wild type CD95 (PS120
CD95) or a death domain-truncated CD95 (PS120
CD95(D1-210))
was incubated with 100 ng/ml of cleaved CD95L for indicated times. Cells were harvested, lyzed, and 100 mg of protein was loaded per lane. Proteins
were resolved in a SDS-PAGE and immunoblots were performed. Phosphorylation of the serine
473 on Akt indicates activation of the kinase. Whole Akt
is added as loading control. (B) Upper panels: PS120
CD95 cells were pre-incubated with non-cytotoxic and non-cytostatic concentration of PI3K
inhibitors (2.5 mM of wortmannin and 5 mM of LY294002), the cell permeant chelator of calcium BAPTA-AM (5 mM), or the inhibitor of IP3-R and SOC
channels 2-APB (20 mM). Cells were then untreated (ctr) or treated for 5 min with 100 ng/ml of cl-CD95L and lysed, 50 mg/ml of protein was loaded
per lane, and indicated immunoblots were performed. Lower panels: densitometry analyses of the immunoblot bands using ImageJ software and the
histograms depict Phospho-Akt/whole Akt ratios. (C) Cell migration of PS120
CD95 was assessed using the Boyden chamber assay. Cells were pre-
incubated with non-cytotoxic and non-cytostatic concentrations of PI3K inhibitors (2.5 mM of Wortmannin and 5 mM of LY294002), the cell permeant
chelator of calcium BAPTA-AM (5 mM), or the inhibitor of SOC channels 2-APB (20 mM) for 30 min and then stimulated with 100 ng/ml of cl-CD95L for
24 h. For each experiment, 10 pictures of the migrating cells were taken and a representative picture was depicted (Bars=50 mm). (D) Cells were
treated as described in (C). To quantitatively measure cell motility, Giemsa-stained migrating cells from the lower side of the membrane were lyzed,
and absorbance was measured at a wavelength of 560 nm. Values represent means and SD of three independently performed experiments. **p,0.01
and ***p,0.001 as calculated using two-tailed non-parametric Mann-Whitney test. (E) The silencing effect of the Orai1-targeting shRNAmir-pGIPZ
vectors was analyzed by immunoblot in lentiviral-transduced HEK cells. 48 h after transduction, cells were lysed and 100 mg of lysates were loaded
per line. b-actin serves as a loading control. (F) Cell migration of indicated shRNAmir-transduced HEK cells was assessed using Boyden chamber assay.
Right panels: HEK cells were transduced with scrambled or Orai1-targeting ShRNA, and 48 h later, cells were incubated for 24 h in the presence or
absence of 100 ng/ml of cl-CD95L. Migrating cells were fixed with methanol and stained by Giemsa. For each experiment, five pictures of random
fields were taken and a representative picture was depicted (Bars=70 mm). Left panel: To quantitatively measure cell motility, Giemsa-stained
migrating cells from the lower side of the membrane were lyzed, and absorbance was measured at a wavelength of 560 nm. Values represent means
and SD of three independently performed experiments. *** p,0.001 as calculated using two-tailed non-parametric Mann-Whitney test.
doi:10.1371/journal.pbio.1001090.g004
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addition, inhibition of Src kinase activity using the pharmacologic
inhibitor PP2 impeded the phosphorylation of Akt, supporting the
notion that src kinases were involved in the transduction of the
CD95-mediated PI3K/Akt signal (Figure 5B). C-yes belongs to the
src family and its activity promotes activation of PI3K in
glioblastoma cells [19]. Strikingly, in activated PBLs and in the
T-cell line H9, we observed that in contrast to the ‘‘canonical
DISC’’ formed in the presence of the agonistic antibody APO1-3,
addition of cl-CD95L failed to induce the binding of FADD,
caspases-8 (Figure 5C), and -10 (unpublished data) to CD95 but
promoted the recruitment of the tyrosine kinase c-yes (Figure 5C).
In contrast, another src kinase termed syk, which is involved in the
BCR (B-cell receptor)-mediated PI3K activation [48], was not
detected in the CD95-containing complex (unpublished data).
These findings indicated that binding of cl-CD95L to CD95
reached the formation of a molecular complex devoid of the
initiator caspases-8 and -10. In agreement with these latter
observations, inhibition of the caspase activity using the broad-
spectrum caspase inhibitor zVAD-fmk did not alter Akt phos-
phorylation (Figure 5B) and cell motility (Figure S9A and S9B).
Next, the role of src kinases in the cl-CD95L-mediated cell motility
was explored. Using Boyden chamber and wound healing assays,
we demonstrated that the src kinase inhibitor PP2 completely
abrogated the cl-CD95L-mediated cell motility (Figure 5D and
S10A). Likewise, activated PBLs underwent a significant increase
in their migration across a vascular endothelial monolayer in the
presence of cl-CD95L as compared with control medium and both
PP2 and LY294002 hindered the transmigration process
(Figure 5E). To ascertain that c-yes participated in igniting the
CD95-mediated motility signal, cells were transduced with c-yes
shRNA-encoding lentiviral vectors. (Figure 5F). C-yes silencing
prevented the cl-CD95L-mediated Akt activation (Figure 5G) and
thus abrogated both the cell migration of the non-hematological
cell line PS120
CD95 (Figures 5H and S9B) and the transmigration
of T-cells across endothelial cells (Figure 5I). Overall, these
findings provide unique evidence that the naturally processed
CD95L elicits a non-apoptotic signal through the formation of a
‘‘non-canonical’’ DISC devoid of FADD and caspases-8/-10 but
encompassing the tyrosine kinase c-yes. This newly disclosed
molecular complex was designated MISC for motility-inducing
signaling complex.
Incubation of Activated Lymphocytes with Sera of SLE
Patients Induces Endothelial Adhesion and
Transmigration
Since in murine model of systemic lupus erythematosus (SLE)
ectopic expression of CD95L leads to a dramatic exacerbation of
the disease index, we wondered whether cleaved CD95L was
found increased in SLE-affected patients as compared to healthy
individuals. We observed that the CD95L level was significantly
higher in sera from SLE patients (431.286301.8 pg/ml) than in
healthy donors (217.126125.8 pg/ml) (p=0.008) (Figure 6A).
Furthermore, we showed that the level of soluble CD95L was
inversely correlated with two markers of the disease activity,
complement C3 (R
2=0.51, p=0.0026) and C4 (R
2=0.51,
p=0.0007) (Figure 6B). In this regard, we propose that serum
CD95L may serve as a solid surrogate marker for the
inflammatory progression of the disease in SLE patients.
Next, to address whether CD95L found in sera of SLE patients
behaves similarly to the one produced in vitro, we incubated
activated PBLs with control or SLE sera and analyzed cell
morphology by contrast phase and plasma membrane distribution
of CD95 using confocal microscopy. Sera from healthy donors
induced neither clustering of CD95 at the plasma membrane nor
alteration of the cell morphology, whereas sera from lupus patients
dramatically aggregated CD95 at the plasma membrane of
activated lymphocytes. Similar to observations obtained with cl-
CD95L produced in 293 cells, CD95-CAP was found distributed
at the extremity of the emitted pseudopod (see red arrows in
Figure 6C). In addition, both modification of cell morphology and
formation of CD95-CAP were abrogated by pre-incubating cells
with anti-CD95 blocking mAb (clone ZB4, unpublished data).
To decipher whether the increased amount of CD95L found in
SLE patients compared to healthy individuals was able to trigger
cell motility, titration of CD95L was applied on PS120 and
PS120
CD95 and motility was assessed using wound healing assay.
Doses of cleaved CD95L as low as 500 pg/ml efficiently promoted
cell migration of PS120
CD95 cells, while 250 pg/ml of CD95L was
totally inefficient to enhance the basal motile pattern of these cells
(Figure 6D). As previously mentioned, cells underwent migration
through a CD95-driven mechanism, since CD95-deficient PS120
did not occur in cell migration upon addition of cleaved-CD95L
(Figure 6D). Interestingly, 500 pg/ml of soluble CD95L was
around the median concentration measured in SLE patients
(431 pg/ml), while 250 pg/ml corresponded to the median
concentration found in healthy donors (253 pg/ml) (Figure 6A).
Finally, to establish that cleaved-CD95L promotes extravasation
of activated T-lymphocytes, a process that is instrumental in
accumulating T-cells in inflamed tissues and thus in fuelling the
inflammatory process, activated T-lymphocytes were incubated
either with SLE or healthy sera and both adhesion on and
transmigration across endothelial cells were quantified. In the
presence of SLE sera, activated T-lymphocytes underwent a
significant increase in their adherence (461.21 versus 260.4610
4
cell equivalent, for SLE versus control sera, p,0.05) (Figure 6E)
and migration across a vascular endothelial monolayer (Figure 6E)
as compared with T-lymphocytes incubated in sera from healthy
donors. In addition, blocking the CD95/CD95L interaction with
an anti-CD95 neutralizing mAbs (clone ZB4) impeded both
adhesion and transmigration of the activated T-cells. In summary,
these findings indicated that the high amounts of cleaved-CD95L
found in lupus patients promote T-lymphocyte extravasation and
accumulation of the immune cells in inflamed tissues.
Discussion
Most of the experiments aiming to understand the biological
functions of CD95L have focused on its transmembrane moiety or
engineered soluble CD95L mimicking the multimerized mem-
brane-bound ligand. However, using the physiological soluble
CD95L, which is the result of its membrane shedding, we
demonstrated for the first time, to our knowledge, that this
cytokine released in the circulation behaves as a potent inducer of
non-canonical (caspase-independent) and non-apoptotic signals
that causes endothelial transmigration of activated T-lymphocytes.
Cleaved CD95L induces the rapid emission of pseudopods in both
activated lymphocytes and fibroblastic cells and subsequently
promotes cell motility through a c-yes/Orai1/Ca
2+/PI3K signal.
Recent studies have revealed that a localized Ca
2+ rise occurs
beneath the immune synapse upon the TCR engagement through
the activation of the Ca
2+ release-activated Ca
2+ (CRAC) channel
consisting of STIM1 and Orai1 [53]. STIM-1 is an ER-store Ca
2+
sensing molecule [38,39,41] that links store depletion to Orai1
aggregation, which in turn leads to the selective Ca
2+ entry. In this
study, we ascertain that the CRAC channel consisting of the pore-
forming subunit Orai1 plays a crucial role in the Ca
2+ entry
observed in the presence of cl-CD95L. In addition, this Ca
2+
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PLoS Biology | www.plosbiology.org 8 June 2011 | Volume 9 | Issue 6 | e1001090Figure 5. The src kinase c-yes orchestrates the cl-CD95L-mediated PI3K/Akt signaling pathway and cell migration. (A) Upper panels:T -
leukemic cell line H9 was transiently transfected with Lck-GFP. 24 h after transfection, living cells were treated or untreated for the indicated times in
the presence of cl-CD95L (100 ng/ml). CD95 was stained using a mouse anti-CD95 mAb and a goat Alexa555-coupled anti-mouse IgG mAb. Lower
panels: Activated PBLs were incubated for the indicated times with 100 ng/ml of cl-CD95L, and then cells were fixed. Lipid rafts were stained using
Alexa488-cholera toxin B subunit and CD95 was followed as previously mentioned. Images were acquired with a confocal microscope with a 636
objective. Cell morphology was followed using phase contrast microscopy (Bars=7.5 mm). The percentage of T-cells displaying a CD95 cluster was
assessed (,300 cells counted for each condition). Among the activated T-lymphocytes showing CD95 cluster, the amount of CD95-CAP co-localized
with lipid rafts was assessed. (B) H9 T-cells were pre-incubated for 30 min with DMSO (U), 10 mM of PP2, 5 mM of LY294002 (LY), 2.5 mMo f
wortmannin (Wort), or 40 mM of zVAD-fmk (zV) and then treated or untreated for 15 min with 100 ng/ml of cl-CD95L. Cells were lyzed and Akt
phosphorylation (S
473) and whole Akt were assessed by immunoblots. (C) The H9 T-cell line (left panels) and activated PBLs (right panels) were
incubated for indicated times with 100 ng/ml of cl-CD95L or APO1-3. Then, cells were lyzed and CD95 was immunoprecipitated. The immune
complex was resolved in a 10% SDS-PAGE, and indicated immunoblots were performed. Total lysates were depicted to confirm that the same amount
of protein was present for each immunoprecipitation. The black stars represent heavy chains of Ig. (D) Boyden chamber assays were performed as
described in Materials and Methods. PS120
CD95 were pre-incubated with or without a non-cytotoxic and non-cytostatic concentration of PP2 (10 mM)
for 30 min and then treated (cl-CD95L) or untreated (2) for 24 h with 100 ng/ml of cl-CD95L. Data are representative of three independently
performed experiments. (E) Activated PBLs were pre-incubated with 10 mM of the src inhibitor PP2 or 5 mM of the PI3K inhibitor LY294002 (LY) and
then incubated in the presence or absence of cl-CD95L (100 ng/ml) for 24 h. Then, endothelial transmigration of PBLs was assessed as described in
Materials and Methods. (F) The silencing effect of the c-yes-targeting shRNAmir-pGIPZ vectors was analyzed by immunoblot in lentiviral-transduced
PS120
CD95 cells. 72 h after transduction, cells were lysed and 100 mg of lysate was loaded per line. b-actin serves as loading control. (G) The T-cell line
H9 was transduced with scramble (scr) or c-yes (shYes#3)-targeting shRNAmir-containing lentivirus. 72 h after transduction, living cells were
harvested and green cells were sorted by flow cytometry using FACSAria. Cells were immediately stimulated or unstimulated with cl-CD95L (100
ng/ml), and the amounts of Akt phosphorylation (S
473) were assessed by immunoblot. (H) Cell migration of indicated shRNAmir-transduced
PS120
CD95 was assessed using the Boyden chamber assay. Left panels: 72 h after transduction, cells were treated (cl-CD95L) or untreated (mock) with
100 ng/ml of cl-CD95L for 24 h. For each experiment, five pictures of the migrating cells were taken and a representative picture was depicted
(Bars=50 mm). Right panel: To quantitatively measure cell motility, Giemsa-stained migrating cells from the lower side of the membrane were lyzed
and absorbance was measured at a wavelength of 560 nm. Values represent means and SD of three independently performed experiments. (I) H9
cells were transduced as mentioned in (G), and the green cells were incubated in the presence or absence of cl-CD95L (100 ng/ml) for 24 h. Then, the
endothelial transmigration of the sh-RNA-expressing T-cells was assessed as described in Materials and Methods.
doi:10.1371/journal.pbio.1001090.g005
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display a homogeneous cytosolic distribution but instead consti-
tutes a Ca
2+ microdomain localized at the leading edge of the cell
protrusion emitted by the migrating cells. This heterogeneous
Ca
2+ distribution has recently been described as essential in
steering cell migration [33] and we speculate that the Ca
2+
microdomain observed contiguous to the CD95-CAP may play a
similar function. The spatial and temporal co-distribution of the
PI3K activity (production of PIP3), actin polarization, and Ca
2+
increase at the leading edge of the CD95-driven pseudopods
suggests interconnections between these different processes. This
assumption is supported by the fact that failure to induce a calcium
response hinders Akt activation and, as a result, decreases cell
migration. Few publications have reported molecular targets
linking cytosolic Ca
2+ increase to Akt activity; for instance, a
calmodulin-dependent mechanism in glioblastoma [54] and a
PKCa-dependent process in HUVEC [55] enhance Akt phos-
phorylation and thus activation. Nevertheless, the molecular
mechanism underlying the modulation of the Akt activity
following the formation of polarized Ca
2+ microdomains remains
totally unknown and would require further investigation.
Upon CD95 engagement, the proximal molecular events
leading to activation of the non-canonical PI3K signal remains
poorly defined. Here, we underscore that despite the fact that the
CD95-mediated PI3K activation occurs through a death domain
(DD)-dependent mechanism, FADD and the initiator caspases are
not detected in the newly identified CD95-containing complex,
suggesting either that another adaptor protein may participate in
this CD95-mediated ‘‘non-orthodox’’ signal or that undetectable
amounts of FADD remain sufficient to promote both the partition
of CD95 into aggregated lipid rafts and the subsequent activation
of src kinase yes through a yet unknown signaling pathway. In
agreement with this latter notion, it has previously been reported
that 2% of the caspase-8 activity is sufficient to redistribute CD95
Figure 6. CD95L found in SLE patients promotes endothelial transmigration of activated PBLs. (A) By ELISA, the amounts of soluble
CD95L in sera of healthy donors (control) and SLE patients were quantified. n stands for the number of SLE patients and healthy subjects. (B)
Correlation between aggravation markers of the disease and the amount of soluble CD95L. (C) Activated PBLs were incubated for the indicated times
with sera of healthy donors or SLE patients and the distribution of CD95 was analyzed by confocal microscopy. (D) A 24 h wound healing assay was
performed. The fibroblastic cell line PS120
control or its CD95-expressing counterpart PS120
CD95 was grown to confluence. then the monolayer was
‘‘wounded’’ by scratching cells using a pipette tip. Using microscopy, the migration was monitored for 24 h with the indicated concentrations of cl-
CD95L as indicated in Materials and Methods. Pictures are representative of 3 independently performed experiments. (E) Activated PBLs were
incubated in the presence of sera from SLE patients (n=3) or healthy donors (n=6), and then, adhesion to endothelial cells (left panel) and
endothelial transmigration (right panel) of PBLs were assessed as described in Materials and Methods. Where indicated, activated PBLs were
preincubated 30 min with the antagonist anti-CD95 mAb ZB4 (a-CD95). ZB4 was maintained in the culture at 10 mg/ml.
doi:10.1371/journal.pbio.1001090.g006
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thus to evoke the apoptotic signal [56]. However, this assumption
seems unlikely since inhibition of the caspase activity does not
affect either PI3K/Akt activation or cell motility. The newly
disclosed CD95-containing complex, which gathers the src kinase
c-yes, has been designated MISC for Mobility-inducing signaling
complex in comparison with the Death-inducing signaling complex
(DISC) [57]. Recent evidence emphasizes that the tyrosine kinase
c-src abrogates the caspase-8 activity through its phosphorylation
on tyrosine 380, which serves as a docking site for the recruitment
and the activation of p85, the regulatory sub-unit of the class IA
PI3K [58]. Nevertheless, the implication of caspase-8 in the
recruitment and activation of the PI3K signal remains doubtful in
the context of the MISC since no caspase-8 or -10 were detected in
this CD95-containing complex. In conclusion, even if the CD95-
mediated c-yes activation is instrumental in eliciting PI3K/Akt
signal and cell migration, the molecular ordering connecting the
src kinase to the activation of PI3K/Akt remains to be clarified.
Surprisingly, redistribution of CD95 into lipid rafts has initially
been described as a crucial step in the induction of the apoptotic
signal [59–64]. It is tempting to postulate that as we previously
reported [65], at least two different types of lipid rafts can be
gathered around CD95, and thus, according to the composition of
the recruited lipid platform, an opposite signal may be transduced
in the presence of cleaved and membrane-bound CD95L. This
hypothesis has still to be confirmed, and furthermore, our
observations raise the question of how ligands that only diverge
by their stoichiometry may account for the partition of CD95 into
different types of lipid rafts.
This new observation not only is important to better appreciate
the function of seric CD95L in cell biology but also offers the
opportunity to gain insight into mechanisms underlying autoim-
mune disorders. Soluble CD95L was significantly increased in
SLE patients as compared to healthy individuals, and furthermore,
the concentration of CD95L was correlated with the activity of the
autoimmune disease. We were concerned that the mix of cytokines
present in the serum of SLE patients may affect the effect of cl-
CD95L. However, we showed that in contrast to sera from healthy
donors, soluble CD95L present in SLE patients efficiently
achieved clustering of CD95 at the leading edge of the emitted
pseudopods, which promoted both adhesion and transmigration
across endothelial cells of the activated T-lymphocytes. Overall,
the naturally processed CD95L cytokine evokes lymphocyte
motility, which may account for the accumulation of cytotoxic
T-cells in inflamed areas, causing tissue damages associated with
chronic inflammatory disorders. Indeed, cell migration contributes
to leukocyte extravasation and metastasis transition, among others,
and these cellular mechanisms participate in the chronicity of
inflammatory disorders and subsequent malignancy occurrence.
Identification of cleaved-CD95L as a cytokine underlying these
cellular processes may hold promises of new therapeutical
approaches to prevent both tissue infiltration and damages. As a
consequence and counter-intuitively, these findings point out that
soluble CD95L may accelerate tumorigenesis through the
activation of pro-survival, pro-proliferative signals and besides by
promoting cell migration.
In agreement with two recent publications [66,67], the concept
of CD95-mediated apoptosis contributing to elimination of
unwanted and damaged cells can be revisited. Even if the so-
called ‘‘death receptor’’ CD95 is not only dedicated to induce cell
death, the molecular mechanisms finely tuning the switch from
apoptotic to non-apoptosis signals or vice-versa remain unknown.
Herein, we show that a crucial factor monitoring the CD95
signaling pathway is its ligand itself. Indeed, the post-translational
modification consisting in the cleavage by metalloprotease of the
membrane-bound CD95L creates a new ligand displaying totally
different functions. Whereas the membrane-bound CD95L helps
to contract the immune response and maintains peripheral
tolerance, its metalloprotease-cleaved counterparts released in
blood circulation induce non-apoptotic signals promoting cell
migration, which plays a pivotal function in inflammation and
tumorigenesis.
Materials and Methods
Ethics Statement
All clinical investigations have been conducted according to the
principles expressed in the Declaration of Helsinki. Blood was
sampled from patients diagnosed with SLE after written consent
was obtained from each individual. This study was approved by
the Institutional Review Board at the Centre Hospitalier
Universitaire de Bordeaux.
Patients
All SLE patients fulfilled four or more of the 1982 revised ACR
criteria for the disease. C3 and C4 complement components were
measured by nephelometry using commercially available kits
(Siemens Healthcare, Saint Denis, France).
Antibodies, Plasmids, and Other Reagents
BTP2, PP2, LY294002, Wortmannin, BAPTA-AM ([1,2-bis-(o-
Aminophenoxy)ethane-N,N,N9,N9-tetraacetic Acid Tetra-(acetoxy-
methyl) Ester]), and 2-APB (2-Aminoethoxydiphenyl borate) were
purchased from Calbiochem (Merck Chemicals Ltd., Nottingham,
UK). PHA, DAPI, Fura-2AM, FITC-conjugated cholera toxin B
subunit, and DiOC6 were purchased from Sigma-Aldrich (L’Isle-
d’Abeau-Chesnes, France). Anti-Akt and anti-phospho-Akt antisera
werefromCell Signaling Technology,Inc.(Boston,MA,USA).The
homemade soluble CD95L (gp190-CD95L) was generated in the
laboratory [27]. Anti-caspase-8 (C15) was purchased from Axxora
(Coger S.A., Paris, France). Anti-human CD95 mAb (DX2) was
from BD Biosciences (Le Pont de Claix, France). Anti-c-Yes, Anti-
Akt, anti-Akt-phosphoS473-, anti-PLCc1, and anti-phospho-
PLCc1 antibodies were from Cell Signaling Technology (Boston,
MA, USA). The anti-human Orai1 was from Abcam (Paris,
France). Plasmid encoding the EGFP-Lifeact was a kind gift from
Dr. R. Wedlich-So ¨ldner (Max Planck Institute of Biochemistry,
Martinsried, Germany) [32]. Lck-GFP- and PHAkt-GFP-containing
vectors were provided by Dr. Rodgers (Oklahoma Medical
Research Foundation, Oklahoma City, USA) [51] and Dr. T.
Balla (National Institutes of Health, Bethesda, USA) [68],
respectively. The pCR3-FasL-S126E/L127E came from Dr. P.
Schneider (University of Lausanne, Epalinges, Switzerland) [20].
The pEGFP-C2 plasmids encoding GFP-Orai1 and GFP-Or-
ai1E106A were kindly provided by Dr. M. Cahalan (University of
California, Irvine, CA, USA).
Cell Lines and Peripheral Blood Lymphocytes
The human leukemic T-cell line Jurkat and the lymphoma T-
cell line H9 were maintained in RPMI supplemented with 8% v/v
heat-inactivated FCS and 2 mM L-glutamine at 37uCi na5 %
CO2 incubator. 293 cells and the hamster fibroblastic cell line
PS120 were cultured in DMEM supplemented with 8% v/v heat-
inactivated FCS and 2 mM L-glutamine at 37uC in a 5% CO2
incubator. PBMCs (peripheral blood mononuclear cells) from
healthy donors were isolated by Ficoll centrifugation and washed
twice in PBS. Monocytes were removed by a 2 h adherence step
and the naive PBLs (peripheral blood lymphocytes) were
Cleaved CD95L Triggers T-cell Motility
PLoS Biology | www.plosbiology.org 11 June 2011 | Volume 9 | Issue 6 | e1001090incubated overnight in RPMI supplemented with 1 mg/ml of
PHA. Cells were washed extensively and incubated in the culture
medium supplemented with 100 units/ml of recombinant IL-2
(PeproTech Inc., Rocky Hill, NJ, USA) for 6 d. Human umbilical
vein endothelial cells (HUVEC) [69] were grown in human
endothelial serum-free medium (Invitrogen, Cergy Pontoise,
France) supplemented with 20% FCS, 20 ng/ml basics FGF,
10 ng/ml EGF (Invitrogen), and 1 mg/ml heparin (Sigma-
Aldrich).
In order to select stable clones, Jurkat cells were transfected as
previously mentioned and then placed in a medium supplemented
with 1.8 mg/ml of neomycin. GFP-, GFP-Orai1WT, and GFP-
Orai1E106A-expressing cells were cloned by limiting dilutions and
next selected based on their expression of GFP using flow
cytometry. Silencing experiments were performed by lentiviral
transduction of H9 T-cells or PS120
CD95 using validated shRNA-
mir-pGIPZ vectors for c-yes (RHS4430-98843955, -99161516,
-98843955), Orai1 (RHS4430-98715881, -101067842), or a non-
targeting shRNAmir-pGIPZ vector as a negative control (Open
Biosystems, USA). To improve the percentage of transduced
T-cells, living cells were harvested 72 h after transduction and
green cells (pGIPZ encodes GFP) were sorted by flow cytometry
using FACSAria (BD Bioscience).
Cleaved-CD95L Production
293 cells maintained in a 1% FCS-containing medium were
transfected using Calcium/Phosphate precipitation method with
3 mg of empty plasmid or wild type CD95L-containing vector.
Media containing cleaved CD95L and exosome-bound full-length
CD95L were harvested 5 d after transfection. Dead cells and
debris were eliminated through two steps of centrifugation
(4,500 rpm/15 min), and then exosomes were pelleted via an
ultracentrifugation step (100,000
g/2 h). Finally, debris- and exosome-free supernatants were
concentrated (10 kDa cut-off centricon) and dialyzed against PBS.
CD95L ELISA
Anti-CD95L ELISA (Diaclone, Besanc ¸on, France) was per-
formed to accurately quantify the cleaved-CD95L present in sera
following the manufacturer’s recommendations.
Cell Death Assay
Cell viability was assessed using MTT assay, exactly as
previously described [63]. In brief, 4.10
4 cells were cultured for
24 h in flat-bottom, 96-well plates with the indicated concentra-
tions of the apoptosis inducer in a final volume of 100 ml. 15 mlo f
MTT (5 mg/ml in PBS) solution were added, and after 4 h of
incubation at 37uC, the absorbance was measured at 570 nm
wavelength using the Titertek Labsystems Multiskan reader
(Turku, Finland).
Flow Cytometry Analysis
All steps were performed at 4uC. Cells were washed in PBS/1%
(w/v) BSA, washed with PBS, and then stained with anti-CD95
mAb (clone DX2) for 30 min at 4uC. Cells were incubated for
30 min with a FITC-conjugated secon-
fodary antibody and immediately analyzed using FACScalibur (BD
Bioscience).
Immunoblot Analysis
Cells were lyzed for 30 min at 4uC in lysis buffer (25 mM
HEPES pH 7.4, 1% v/v Triton X-100, 150 mM NaCl, 2 mM
EGTA supplemented with a mix of protease inhibitors; Sigma-
Aldrich). Protein concentration was determined by the bicincho-
ninic acid method (PIERCE, Rockford, IL, USA) according to
the manufacturer’s protocol. Proteins were separated on a 12%
SDS-PAGE and transferred to a nitrocellulose membrane (GE
Healthcare, Buckinghamshire, UK). The membrane was blocked
15 min with TBST (50 mM Tris, 160 mM NaCl, 0.05% v/v
Tween 20, pH 7.8) containing 5% w/v dried skimmed milk
(TBSTM). Primary antibody was incubated overnight at 4uCi n
TBSTM. The membrane was intensively washed (TBST), and
then the peroxydase-labeled anti-rabbit or anti-mouse (South-
ernBiotech, Birmingham, Alabama, USA) was added for 45 min.
The proteins were visualized with the enhanced chemilumines-
cence substrate kit (ECL, GE Healthcare).
DISC and MISC immunoprecipitations
The T-cell line H9 and activated PBLs (20.10
6 cells per
condition) were incubated with 1 mg/ml of APO1-3 or 100 ng/ml
cl-CD95L for 15 min at 4uC (0 min) or at 37uC (15 min). Cells
were then lysed and CD95 was immunoprecipitated using protein
A-sepharose beads (Sigma-Aldrich). To immunoprecipitate the cl-
CD95L-induced CD95-containing complex, 1 mg of Apo1-3 was
added in the cell lysate and CD95 was immunoprecipitated as
previously mentioned. After extensive washing, the immune
complex was resolved using a 12% SDS-PAGE.
Immunofluorescence Imaging
Cells were left to adhere 5 min at room temperature to poly-L-
Lysine-coated slides and treated with Ig-CD95L or cl-CD95L for
indicated times at 37uC. After extensive washing, cells were fixed
in PBS containing 4%
w/v paraformaldehyde for 15 min. The aldehyde groups were
quenched for 10 min using a solution of PBS supplemented with
5% FCS. Cells were incubated with 1 mg/ml of the anti-CD95
mAb (APO1-3) for 30 min at 4uC. Finally, CD95 was revealed
using either the Alexa488-conjugated (green) or the Alexa555-
conjugated (red) goat anti-mouse antibody (Molecular Probes,
Cergy Pontoise, France) in PBS/1% w/v BSA for 30 min at 4uC.
Lipid rafts were tagged by FITC-labeled cholera toxin B (CTB).
For Orai1 staining, cells were incubated with APO1-3 and 1
mg/ml of the anti-Orai1 mAb in PBS/1% w/v BSA for 60 min
at room temperature. CD95 was revealed using secondary
Alexa594-coupled goat anti-mouse mAb and Orai1 was observed
using Alexa488-conjugated donkey anti-rabbit mAb (Invitrogen,
Carlsbad, CA, USA) for 60 min at room temperature. Slides were
washed with PBS, dried, and mounted with Fluorescent Mounting
Media (Dako, Carpinteria, CA, USA). Images were acquired with
a confocal microscope TSC SP5 (Leica, Wetzlar, Germany) with a
636objective.
In Vitro Motility Assays
Boyden chamber assay. Boyden chambers (Millipore,
Molsheim, France) containing 8 mm pore size positron emission
tomograph membranes were cultured in 24-well plates. After
hydration of the membranes, 10
5 cells were added to the top
chamber in a low serum (1%)-containing medium. The bottom
chamber was filled with low serum (1%)-containing medium in the
presence or absence of 100 ng/ml of cl-CD95L. Cells were
cultured for 24 h at 37uC in a 5% CO2, humidified incubator. To
quantify invasion, cells were removed from the top side of the
membrane mechanically using a cotton-tipped swab, and invading
cells from the reverse side were fixed with methanol and stained
with Giemsa. For each experiment, five representative pictures
were taken for each insert, then cells were lyzed and absorbance at
560 nm correlated to the amount of Giemsa stain was measured.
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were pre-incubated with inhibitors for 30 min prior to addition in
the top chamber.
Wound healing assay. Cells (10
6) were seeded in a 6-well
plate and cultured until confluence. Next, a straight scratch was
performed in the monolayer of cells using a pipette tip. Imaging of
the two wound edges were performed using the 106objective. For
each condition, images were acquired at five different positions
along the scratch and a representative field was depicted.
Adhesion and Transendothelial Migration of Activated
T-Lymphocytes
Transmigration. Assays for endothelial transmigration
of activated PBLs were performed in Boyden chambers with
polycarbonate filters of 8 mm pore size (Costar). Activated T-
lymphocytes (2610
6) were placed in the upper chamber on a
confluent monolayer of HUVEC. 1 ml of serum from either
healthy or SLE patients was added in the lower reservoir, and after
24 h, transmigrated cells were counted in the lower reservoir by
flow cytometry using a standard of 2.5610
4 fluorescent beads
(Flow-count, Beckman Coulter).
Adherence. Determination of T-lymphocyte adherence to
endothelial monolayers was performed with a fluorescence
multi-well plate reader (Cytifluor, Framingham, MA, USA).
Briefly, 2610
6 activated T-lymphocytes were added to the upper
chamber and 1 ml of different plasma samples in the lower
reservoir. Cells were allowed to adhere for 1 h at 37uC and 5%
CO2 atmosphere, and after extensive washing with HBSS, cell-
associated fluorescence was measured. Results are depicted as
relative mean adherence corresponding to the ratio of fluorescence
values before and after washing.
Video Imaging of Calcium Response in Living Cells
T-cells were loaded with Fura2-AM (1 mM) at resting
temperature for 30 min in Hank’s Balanced Salt Solution (HBSS).
After washing with HBSS, the cells were incubated for 15 min in
the absence of Fura2-AM to complete de-esterification of the dye.
Cells were placed in a thermostated chamber (37uC) of an inverted
epifluorescence microscope (Olympus IX70) equipped with a640,
UApo/340–1.15 W water-immersion objective (Olympus), and
fluorescence micrograph images were captured at 510 nm and at
12-bit resolution by a fast-scan camera (CoolSNAP fx Mono-
chrome, Photometrics). To minimize UV light exposure, 464
binning function was used. Fura2-AM was alternately excited at
340 and 380 nm, and ratios of the resulting images (excitations at
340 and 380 nm and emission filter at 520 nm) were produced at
constant intervals (5 s or 10 s according to the stimulus). Fura-2
ratio (Fratio 340/380) images were displayed and the Fratio values
from the regions of interest (ROIs) drawn on individual cells were
monitored during the experiments and analyzed later offline with
Universal Imaging software, including Metafluor and Metamorph.
Each experiment was independently repeated 3 times, and for
each experimental condition, we displayed an average of more
than 20 single-cell traces. Fluorescent images were pseudocolored
using the IMD display mode in MetaFluor and assembled without
further manipulation in Photoshop (Adobe). Raw data were
acquired with MetaFluor and graphed in Origin (OriginLab).
[Ca
2+]i was calculated using the following equation: [Ca
2+]i=
Kd(R2Rmin)/(R2Rmax)6Sf2/Sf1, where Kd is the Fura2-AM
dissociation constant at the two excitation wavelengths (F340/F380);
Rmin is the fluorescence ratio in the presence of minimal calcium,
obtained by chelating Ca
2+ with 10 mM EGTA; Rmax is the
fluorescence ratio in the presence of excess calcium, obtained by
treating cells with 1 mM ionomycin; Sf2 is the fluorescence of the
Ca
2+-free form; and Sf1 is the fluorescence of the Ca
2+-bound
form of Fura2-AM at excitation wavelengths of 380 and 340 nm,
respectively.
In some experiments cells were placed in a Ca
2+-free medium
consisting of the HBSS described above in which CaCl2 was
omitted and 100 mM EGTA was added in order to chelate
residual Ca
2+ ions. This medium was added to the cells just before
recording to avoid leak of the intracellular calcium stores.
In experiments combining CD95 immuno-staining and Ca
2+
imaging, cells were incubated or not with 100 ng/ml of cleaved-
CD95L at 4uC and then washed. To visualize the plasma
membrane distribution of CD95, the cells were incubated at
4uC with the non-agonistic anti-CD95 mAb DX2 (1 mg/ml)
associated with an Alexa555-coupled goat anti-mouse mAb
(GAM). Finally, the CD95-stained cells were mixed with 1 mM
fura-2AM and cl-CD95L for 30 min at RT in HBSS solution.
CD95 immuno-staining was imaged at the beginning and at the
end of the experiment. Each experiment was independently
repeated 3 times, and for each experimental condition, we
displayed an average of more than 15 single-cell traces.
Supporting Information
Figure S1 The naturally processed CD95L fails to trigger
caspase-8 activation and cell death. (A) The human embryonic
kidney epithelial cell line 293T (HEK) was transfected with wild
type CD95L or the mutated CD95L
S126E/L127E. Cells were lyzed
(Cell) and supernatants were harvested (Sn) 5 d after transfection.
Dead cells were eliminated from the supernatant by centrifugation
(264,000 rpm for 15 min), and then exosomes were pelleted using
ultracentrifugation (100,000 g/2 h) and lyzed (Exo.). White
arrowhead indicates cleaved-CD95L. Black arrowhead depicts
full-length CD95L and the star indicates an unknown processed
CD95L product. (B) The molecular size of cleaved CD95L was
analyzed using size exclusion S-200-HR Sephacryl columns
(Amersham Pharmacia, Orsay, France). Fractions were harvested
and cl-CD95L was dosed by ELISA. (C) Jurkat and H9 T-cells
were treated with 100 ng/ml of the home-made Ig-CD95L
(dodecameric) or the naturally processed CD95L (trimeric), and
activation of caspase-8 was assessed by following the cleavage of
the protease using immunoblot (fragments p41/43 and p18). For
each cell, long exposures of the film are depicted to detect the p18
cleaved fragment. Stars indicate irrelevant bands. (D) Indicated
cells were incubated for 24 h with an engineered dodecameric Ig-
CD95L or the naturally processed homotrimeric CD95L and cell
death was assessed by MTT assay.
(TIF)
Figure S2 Cleaved CD95L induces formation of CD95-Cap at
the extremity of the emitted pseudopod. (A) The leukemic T-cell
line H9 was incubated for indicated times with 100 ng/ml of
cleaved CD95L, and after extensive washing, cells were fixed.
CD95 was stained using an anti-CD95 mAb (APO1-3) and
revealed using the secondary Alexa488-conjugated goat anti-
mouse antibody (Invitrogen, Carlsbad, CA, USA). Number of cells
harboring a CD95-Cap was counted (at least 300 cells counted for
each condition). (B) The leukemic T-cell lines CEM and H9 were
incubated for 30 min in the presence or absence of 100 ng/ml of
cleaved CD95L, and the plasma membrane distribution of CD95
was then analyzed as described in (A). The quantity of cells
harboring a CD95-Cap was assessed by counting (300 cells/
condition). Values represent means and SD of three independently
performed experiments. **p,0.01 and ***p,0.001 as calculated
using non-parametric and two-tailed Mann-Whitney test. (C)
Leukemic T-cells H9 and CEM were untreated (control) or treated
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washing, cells were fixed. CD95 was stained using an anti-CD95
mAb (APO1-3) and revealed using a secondary Alexa488-
conjugated goat anti-mouse antibody. Nuclei were stained with
DAPI (blue). Slides were washed with PBS, dried, and mounted
with Fluoromount (Cliniscience SAS, Montrouge, France). Red
arrows depict emitted pseudopods upon CD95 engagement.
Images were acquired with a confocal microscope TSC SP5
(Leica, Wetzlar, Germany) with a ApoPLAN 636objective.
(TIF)
Figure S3 CD95 and truncated CD95(1-210)-expressing PS120
clones. (A) Upper panel: analysis of the CD95 expression at
the surface of the indicated PS120 clones stably expressing
either the CD95 wild type or its death domain truncated
counterpart (D1-210). Cells were stained with an anti-CD95
mAb (clone DX2), washed, and a PE-coupled goat anti-mouse
secondary antibody was used to reveal plasma membrane CD95
by flow cytometry. Lower panel: for each staining, the mean of the
fluorescence intensity (MFI), which is correlated to the amount of
plasma membrane CD95, was depicted. (B) Indicated PS120
clones expressing either empty vector (PS120
control), truncated
(PS120
CD95(D1-210)), or wild type CD95 (PS120
CD95) were incu-
bated with the cytotoxic Ig-CD95L or the cleaved CD95L for 24 h
and cell death was quantified using viability assay MTT.
(TIF)
Figure S4 Cleaved CD95L triggers a pseudopod-localized Ca
2+
rise. Video imaging on living cells: Before application of cl-CD95L,
activated T-lymphocytes were loaded with the Ca
2+ indicator
Fura-2AM along with EGTA-AM (1 mM, 30 min, room temper-
ature), a slow high-affinity Ca
2+ buffer. Under these conditions,
Ca
2+ entering the cell would bind rapidly to the Ca
2+ probe,
producing a fluorescent signal, and then be captured by EGTA.
Activated T-lymphocytes were bathed in an external medium
containing 2 mM Ca
2+ and stimulated with 100 ng/ml of
cl-CD95L just after the capture of the ratio images (0 s). Pictures
were recorded at the indicated times following the addition of
cl-CD95L to assess the formation of localized Ca
2+ influx. Emitted
pseudopods were depicted using a white square, and cell migration
is indicated by a white arrow. Grey levels were translated to false
colors according to a scale shown on the right.
(TIF)
Figure S5 The cl-CD95L-mediated calcium response occurs
through a PLCc1/IP3-R-dependent process. (A) The T-cell line
Jurkat was incubated for the indicated times with 100 ng/ml of cl-
CD95L, and then cells were lyzed. 100 mg of protein was loaded
per lane and resolved in a 10% SDS-PAGE. Immunoblots were
performed using indicated mAbs (Cell Signaling technology,
Ozyme, Saint Quentin, France). (B) Left panel: The PLC-c1-
deficient T-cell Jurkat and its PLC-c1-reconstituted counterpart
were loaded with the calcium probe Fura2-AM (1 mM, 30 min at
RT) and then stimulated with 100 ng/ml of cl-CD95L. Ratio
images were taken every 10 s. Regions of Interest (ROIs) outlining
individual cells were defined in three independent experiments,
and the mean ratio in each ROI was plotted versus time. Ratio
values were converted to [Ca
2+]i values using a calibration curve
(see Materials and Methods section). Right panel: Statistical analyses
of the AUC values for the indicated T-cells. *** p values#0.001
using non-parametric two-tailed Mann-Whitney test. (C, D) Left
panels: Jurkat (C) and H9 (D) T-cells were loaded as previously
mentioned. The IP3-R inhibitor, 2-APB (20 mM), was applied
during the recording as indicated by the unfilled rectangle. Then
cells were stimulated with 100 ng/ml of cl-CD95L (black arrow)
and the intracellular Ca
2+ was recorded every 10 s. Regions of
Interest (ROIs) outlining individual cells were defined in three
independently performed experiments and the mean ratio in each
ROI was plotted versus time. Ratio values were converted to
[Ca
2+]i values using a calibration curve (see Materials and
Methods section). Values depict the mean 6 SD of the area
under the curve (AUC) calculated for 1,000 s. Right panels:
statistical analyses of the AUC values. *** p value#0.001 using
non-parametric two-tailed Mann-Whitney test.
(TIF)
Figure S6 Extracellular Ca
2+ plays a crucial role in the
cl-CD95L-mediated Ca
2+ rise. (A) Indicated T-cells were loaded
with 1 mM of the calcium probe Fura-2AM for 30 min at
RT. Cells were bathed at 37uC in a medium containing 2 mM
Ca
2+ (2 mM [Ca
2+]e)o raC a
2+-free medium (0 mM [Ca
2+]e) and
then untreated (vehicle) or treated (cl-CD95L) with 100 ng/ml of
cl-CD95L. Values were recorded every 10 s. Regions of Interest
(ROIs) outlining individual cells were defined in three indepen-
dently performed experiments and the mean ratio in each ROI
was plotted versus time. Ratio values were converted to [Ca
2+]i
values using a calibration curve (see Materials and Methods
section). For each treatment, the mean 6 SD of the area under the
curve (AUC) measured for 1,000 s in individual cells is depicted.
Basal and maximal levels of [Ca
2+]i are indicated by red and blue
dotted lines, respectively. (B) Statistical analyses of the AUC values
for indicated cells incubated in the presence of cl-CD95L in a
regular (2 mM) or a Ca
2+-free medium (0 mM). Using non-
parametric two-tailed Mann-Whitney test, *** indicates a p
value#0.001. (C) PBLs were untreated (upper panel) or treated
(lower panel) with the SOC channel inhibitor BTP-2 (500 nM)
and then 100 ng/ml of cl-CD95L was added. For each condition,
the mean 6 SD of the area under the curve (AUC) measured for
1,000 s is depicted. Basal and maximal levels of [Ca
2+]i are
indicated by red and blue dotted lines, respectively. Note that
individual calcium oscillations and/or synchronous calcium
oscillations (upper panel) lead to apparent calcium oscillations
during the plateau phase.
(TIF)
Figure S7 BAPTA-AM abrogates the cl-CD95L-mediated Ca
2+
response. (A) H9 T-cells were loaded with 1 mM of the calcium
probe Fura-2AM for 30 min at RT. Cells were pre-incubated or
not with BAPTA-AM (5 mM) and then stimulated with 100 ng/ml
of cl-CD95L. Values were recorded every 10 s. Regions of Interest
(ROIs) outlining individual cells were defined in three indepen-
dently performed experiments, and the mean ratio in each ROI
was plotted versus time. Ratio values were converted to [Ca
2+]i
values using a calibration curve (see Materials and Methods
section). For each treatment, the mean 6 SD of the area under the
curve (AUC) measured for 1,000 s is depicted. (B) Statistical
analyses of the AUC values for H9 T-cells treated or untreated
with 5 mM of BAPTA-AM and stimulated with cl-CD95L. Using
non-parametric two-tailed Mann-Whitney test, *** indicates a p
value#0.001.
(TIF)
Figure S8 Identification of the p110 isoform eliciting the cl-
CD95L-mediated cell motility. (A) The table depicts IC50 (nM) of
the different isoform-selective inhibitors on the class I PI3Ks.
PI3K-a Inh-IV (3-(4-Morpholinothieno[3,2-d]pyrimidin-2-yl)phe-
nol); PI3K-b Inh-VI/TGX-221 ((6)-7-Methyl-2-(morpholin-4-yl)-
9-(1-phenylaminoethyl)-pyrido[1,2-a]-pyrimidin-4-one); PI3K-c
Inh (5-Quinoxalin-6-ylmethylene-thiazolidine-2,4-dione); PI3K-d
Inh-X, IC87114; and Wortmannin and LY294002 were tested to
ascertain the isoform involved in the cl-CD95L-mediated motility.
All the inhibitors came from Calbiochem (Merck Chemicals Ltd.,
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2009, Cancer Research, 69(3):1027-36/Hayakawa et al., 2006,
Bioorganic & Medicinal Chemistry, 14(20):6847-58. (B, C, D, and E)
For each inhibitor, the concentrations used in the different in cellulo
assays were defined according to the respective isoform-selective
IC50 indicated in bold in (A). The T-cell line H9 (B) and the
fibroblastic cell line PS120
CD95 (C) were pre-incubated with the
indicated concentrations of the pan-PI3K inhibitors wortmannin
and LY294002 or the isoform-selective inhibitors PI3K-a Inh-IV
(a); PI3K-b inh-VI (b); PI3K-c Inh (c); and PI3K-d Inh-X (d)
for 60 min and then untreated (U) or treated for 30 min with
100 ng/ml of cl-CD95L. Cells were lyzed and 100 mg of protein
was loaded for each lane. Indicated immunoblots were performed.
Bands were scanned and a densitometry analysis was performed
using ImageJ. Values below the immunoblots indicate the
percentage of phospho-Akt inhibition reached with each selective
inhibitor. Data are representative of three independently per-
formed experiments. (D) H9 T-cells were pre-incubated with
a concentration of the indicated PI3K inhibitors corresponding
to 100-fold their predicted IC50 (see A) for 60 min, and then
cells were incubated in the presence or absence of cl-CD95L
(100 ng/ml) for 24 h in a Boyden Chamber in which the porous
membrane was covered with a confluent monolayer of endothelial
cells (see Materials and Methods). Then, the endothelial
transmigration of the T-cells was assessed as described in Materials
and Methods. (E) The fibroblastic PS120
CD95 cell line was pre-
incubated with a concentration of the indicated PI3K inhibitors
corresponding to 100-fold their predicted IC50 (see A) for 60 min,
and then cells were incubated in the presence or absence of
cl-CD95L (100 ng/ml) for 24 h in a Boyden Chamber assay. To
quantitatively measure cell motility, Giemsa-stained migrating
cells from the lower side of the membrane were lyzed and
absorbance was measured at a wavelength of 560 nm. Values
represent means and SEM of three independently performed
experiments.
(TIF)
Figure S9 The caspase activity does not participate in the cl-
CD95L-induced cell motility. (A) Wound healing assays: A confluent
monolayer of the indicated adherent cells was wounded with a tip.
Then, cells were pre-incubated for 30 min with 40 mM of zVAD-
fmk and treated or untreated for 24 h with 100 ng/ml of cl-
CD95L and pictures were acquired (Bars=50 mm). Pictures are
representative of three independently performed experiments. (B)
Upper panels: The CD95-expressing PS120 cells were pre-incubated
with or without the pan-caspase inhibitor zVAD-fmk (40 mM) for
30 min and then seeded in the upper compartment of the Boyden
chamber in a low FCS (1%)-containing medium. Cells were
incubated for 24 h in the presence of absence of 100 ng/ml of cl-
CD95L. Then the membrane was removed, the upper side
containing the non-migrating cells was wiped out with cotton-
tipped swabs, and migrating cells in the opposite side of the filter
were fixed with methanol and stained by Giemsa (purple cells). For
each experiment, five pictures of random fields were taken and a
representative picture was depicted (Bars=70 mm). Lower panel:T o
quantify cell motility, Giemsa-stained migrating cells from the
lower side of the membrane were lyzed and absorbance was
measured at 560 nm. Data represent means and SD of three
independently performed experiments.
(TIF)
Figure S10 The src kinase c-yes is instrumental in the cl-
CD95L-induced cell motility. (A) Wound healing assays: A confluent
monolayer of PS120
CD95 adherent cells was wounded with a tip.
Cells were pre-incubated with or without 10 mM of the src
inhibitor PP2 and then were treated or untreated for 24 h with
100 ng/ml of cl-CD95L. Pictures were acquired to assess the
efficiency of the wound healing. Dotted red lines delineate the
initial position of the wound. (B) PS120
CD95 Cells were transduced
with lentiviral particles containing a c-yes-targeting shRNAmir
or a scramble shRNAmir (OpenBiosystem, USA). 48 h after
transduction, the confluent monolayer of cells was wounded and
cell migration was analyzed in the presence of 100 ng/ml of cl-
CD95L for the indicated time. Pictures are representative of three
independently performed experiments.
(TIF)
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